CY2025 Medicare Advantage Proposed Rule

Back to Resources
ATIInsights
11/08/2023
AUTHOR – ATI Advisory

On November 6, 2023, CMS released its Contract Year 2025 Medicare Advantage and Part D Proposed Rule [CMS-4205-P]. ATI Advisory prepared a summary of key provisions and insights across D-SNP and dual eligible impacts, supplemental benefits, Part D formularies, network adequacy, agent and broker commissions, and equity-related provisions. The Rule has a heavy focus on beneficiary protections and program transparency.

For more information about how ATI Advisory can help you navigate research, policy, operational, or strategic issues, please contact us at info@atiadvisory.com.

Recent Insights

Insights

Two Ways CMS Can Meaningfully Improve Medicare Plan Finder for People Who Are Dual Eligible

With support from Arnold Ventures, ATI Advisory identified two near-term opportunities to update the Medicare Plan Finder tool to improve its utility and reduce confusion for individuals who are dual eligible.
Read More Read More
Insights

Heeding the Administrator’s Call: Opportunities to Improve Supplemental Benefit Data

Medicare Advantage (MA) plans are able to offer additional benefits over the benefits all Medicare beneficiaries receive – called supplemental benefits. These supplemental benefits most typically take the form of vision, dental, hearing, and medical transportation services, but the types of benefits offered are evolving rapidly to include things like in-home support services or personal care, food, and help paying utility bills. Improving data available on these supplemental benefits in MA is clearly on the minds of officials at the Centers for Medicare and Medicaid Services (CMS).
Read More Read More
Insights

What Everyone Is Missing About CMS’ Coverage Of Alzheimer’s Drugs

Few drugs have triggered as much controversy and debate as those for Alzheimer’s Disease. So, it should come as no surprise that last week’s update from Centers for Medicare and Medicaid Services (CMS) on its coverage for these treatments would trigger a wide range of responses. Some outlets reported that CMS was broadening its coverage, even as other groups stated that the agency was limiting access. Others argued that the update heralded no change at all.
Read More Read More
See more Insights
Share
LinkedIn / /